市場調查報告書
商品編碼
1451500
2024-2032 年組織工程市場報告(按類型、應用、最終用戶和地區)Tissue Engineering Market Report by Type, Application, End User, and Region 2024-2032 |
2023年全球組織工程市場規模達180億美元。展望未來, IMARC Group預計到2032年市場規模將達到484億美元,2024-2032年複合年成長率(CAGR)為11.3%。
組織工程(TE)是一門生物醫學工程學科,它將細胞、支架和生物活性分子結合成功能組織。它應用生命科學和工程學的原理來開發生物替代品來恢復、改善、維持或替換不同類型的組織或器官。它為移植、外科重建手術和其他用於修復受損組織的機械裝置提供了有效的替代方案。因此,組織工程在許多醫療應用中迅速獲得關注,包括燒傷治療、神經病學、傷口護理、骨科、肌肉骨骼、心血管和泌尿科產品。如今,研究人員正專注於開發用於皮膚替代的生物材料,以滿足對相對便宜且易於獲得的皮膚替代產品不斷成長的需求。
組織工程程序已被證明可以有效治療組織的不可逆損傷。這導致再生醫學和 TE 手術的需求顯著增加,這是推動市場成長的主要因素。除此之外,致命道路事故和外傷發生率的上升,以及患者對骨植入物的需求不斷成長,都增加了產品需求。此外,由於久坐的生活習慣、人口老化和不健康飲食,糖尿病、癌症、肥胖和心血管疾病等慢性病的廣泛流行正在促進市場成長。此外,3D(3D)組織工程領域的技術進步,例如器官晶片技術、以幹細胞取代胚胎細胞以及使用3D生物列印機有效設計體外植入物,正在提供利潤豐厚的市場機會。此外,多項產品創新以及政府資助和私人對研發(R&D)活動的投資不斷增加正在推動市場成長。其他因素,包括替換和重建手術數量的增加、消費者醫療保健支出的增加以及整形手術需求的激增,也創造了積極的市場前景。
The global tissue engineering market size reached US$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.
Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.
Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global tissue engineering market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.
Synthetic Scaffold Material
Biologically Derived Scaffold Material
Others
Orthopedics and Musculoskeletal
Neurology
Cardiovascular
Skin and Integumentary
Dental
Others
Hospitals and Clinics
Ambulatory Facilities
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.